Pfizer achieved positive results from a Phase III study of the investigational compound bosutinib as a first-line treatment in patients with Philadelphia chromosome positive (Ph+) chronic myeloid leukemia (CML). A significantly higher proportion of patients with newly diagnosed CML treated with bosutinib (39%) experienced a major molecular response (MMR), a secondary endpoint, compared with patients treated with imatinib (26%) in the intent-to-treat (ITT) population. However, the study did not m...